Many inhibitors of these other interactors are already being explored in clinical trials, and these studies provide a rationale for further clinical investigation of menin inhibitors in combination with other epigenetic therapies—even those that appear to have minimal efficacy as single agents—to determine if the preclinical evidence discussed in this review can be translated more effective means of treating relapsed and refractory AML. This evidence concerns the gene MEN1 and acute myeloid leukemia.